Visakorpi T - Search Results

1

miR-32 promotes MYC-driven prostate cancer.

Scaravilli M, Koivukoski S, Gillen A, Bouazza A, Ruusuvuori P, Visakorpi T, Latonen L. Scaravilli M, et al. Among authors: visakorpi t. Oncogenesis. 2022 Mar 1;11(1):11. doi: 10.1038/s41389-022-00385-8. Oncogenesis. 2022. PMID: 35228520 Free PMC article.

2

Probabilistic analysis of gene expression measurements from heterogeneous tissues.

Erkkilä T, Lehmusvaara S, Ruusuvuori P, Visakorpi T, Shmulevich I, Lähdesmäki H. Erkkilä T, et al. Among authors: visakorpi t. Bioinformatics. 2010 Oct 15;26(20):2571-7. doi: 10.1093/bioinformatics/btq406. Epub 2010 Jul 14. Bioinformatics. 2010. PMID: 20631160 Free PMC article.

3

Androgen regulation of micro-RNAs in prostate cancer.

Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G, Visakorpi T. Waltering KK, et al. Among authors: visakorpi t. Prostate. 2011 May;71(6):604-14. doi: 10.1002/pros.21276. Epub 2010 Oct 13. Prostate. 2011. PMID: 20945501

4

Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.

Urbanucci A, Sahu B, Seppälä J, Larjo A, Latonen LM, Waltering KK, Tammela TL, Vessella RL, Lähdesmäki H, Jänne OA, Visakorpi T. Urbanucci A, et al. Among authors: visakorpi t. Oncogene. 2012 Apr 26;31(17):2153-63. doi: 10.1038/onc.2011.401. Epub 2011 Sep 12. Oncogene. 2012. PMID: 21909140

5

Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.

Siltanen S, Wahlfors T, Schindler M, Saramäki OR, Mpindi JP, Latonen L, Vessella RL, Tammela TL, Kallioniemi O, Visakorpi T, Schleutker J. Siltanen S, et al. Among authors: visakorpi t. PLoS One. 2011;6(10):e26595. doi: 10.1371/journal.pone.0026595. Epub 2011 Oct 20. PLoS One. 2011. PMID: 22028916 Free PMC article.

6

Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.

Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL, Visakorpi T. Jalava SE, et al. Among authors: visakorpi t. Oncogene. 2012 Oct 11;31(41):4460-71. doi: 10.1038/onc.2011.624. Epub 2012 Jan 23. Oncogene. 2012. PMID: 22266859

7

Mapping of the chromosomal amplification 1p21-22 in bladder cancer.

Scaravilli M, Asero P, Tammela TL, Visakorpi T, Saramäki OR. Scaravilli M, et al. Among authors: visakorpi t. BMC Res Notes. 2014 Aug 18;7:547. doi: 10.1186/1756-0500-7-547. BMC Res Notes. 2014. PMID: 25135188 Free PMC article.

8

MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets.

Rane JK, Scaravilli M, Ylipää A, Pellacani D, Mann VM, Simms MS, Nykter M, Collins AT, Visakorpi T, Maitland NJ. Rane JK, et al. Among authors: visakorpi t. Eur Urol. 2015 Jan;67(1):7-10. doi: 10.1016/j.eururo.2014.09.005. Epub 2014 Sep 16. Eur Urol. 2015. PMID: 25234358

9

MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2.

Scaravilli M, Porkka KP, Brofeldt A, Annala M, Tammela TL, Jenster GW, Nykter M, Visakorpi T. Scaravilli M, et al. Among authors: visakorpi t. Prostate. 2015 Jun;75(8):798-805. doi: 10.1002/pros.22961. Epub 2015 Mar 1. Prostate. 2015. PMID: 25731699

10

Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.

Annala M, Kivinummi K, Tuominen J, Karakurt S, Granberg K, Latonen L, Ylipää A, Sjöblom L, Ruusuvuori P, Saramäki O, Kaukoniemi KM, Yli-Harja O, Vessella RL, Tammela TL, Zhang W, Visakorpi T, Nykter M. Annala M, et al. Among authors: visakorpi t. Oncotarget. 2015 Mar 20;6(8):6235-50. doi: 10.18632/oncotarget.3359. Oncotarget. 2015. PMID: 25749039 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

293 results

Search Page